Novartis backs Gamida Cell’s $40M raise to fund a looming PhIII study, marketing and manufacturing prep
Israel’s Gamida Cell now has the cash it needs to execute on a late-stage trial for its experimental cell graft, which it hopes can be …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.